Literature DB >> 27581610

Outcomes of Concurrent Breast and Gynecologic Risk Reduction Surgery.

Irene T Ma1, Richard J Gray1, Nabil Wasif1, Kristina A Butler2, Jeffrey L Cornella2, Javier F Magrina2, Paul M Magtibay2, William J Casey3, Raman Mahabir3, Alanna M Rebecca3, Katherine S Hunt4, Barbara A Pockaj5.   

Abstract

BACKGROUND: Women considering risk reduction surgery after a diagnosis of breast/ovarian cancer and/or inherited cancer gene mutation face difficult decisions. The safety of combined breast and gynecologic surgery has not been well studied; therefore, we evaluated the outcomes for patients who have undergone coordinated multispecialty surgery.
METHODS: We conducted a retrospective review of patients undergoing simultaneous breast and gynecologic surgery for newly or previously diagnosed breast cancer and/or an inherited cancer gene mutation during the same anesthetic at a single institution from 1999 to 2013.
RESULTS: Seventy-three patients with a mean age of 50 years (range 27-88) were identified. Most patients had newly diagnosed breast cancer or ductal carcinoma in situ (62 %) and 28 patients (38 %) had an identified BRCA mutation. Almost all gynecologic procedures were for risk reduction or benign gynecologic conditions (97 %). Mastectomy was performed in 39 patients (53 %), the majority of whom (79 %) underwent immediate reconstruction. The most common gynecologic procedure involved bilateral salpingo-oophorectomy, which was performed alone in 18 patients (25 %) and combined with hysterectomy in 40 patients (55 %). A total of 32 patients (44 %) developed postoperative complications, most of which were minor and did not require surgical intervention or hospitalization. Two of the 19 patients who underwent implant reconstruction (11 %; 3 % of the entire cohort) had major infectious complications requiring explantation.
CONCLUSION: Combined breast and gynecologic procedures for a breast cancer diagnosis and/or risk reduction in patients can be accomplished with acceptable morbidity. Concurrent operations, including reconstruction, can be offered to patients without negatively impacting their outcome.

Entities:  

Mesh:

Year:  2016        PMID: 27581610     DOI: 10.1245/s10434-016-5479-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  A Clinical Decision Support Tool to Predict Cancer Risk for Commonly Tested Cancer-Related Germline Mutations.

Authors:  Danielle Braun; Jiabei Yang; Molly Griffin; Giovanni Parmigiani; Kevin S Hughes
Journal:  J Genet Couns       Date:  2018-03-02       Impact factor: 2.537

2.  Concurrent Prophylactic Mastectomy, Immediate Reconstruction, and Salpingo-Oophorectomy in High-Risk Patients: A Case Series.

Authors:  Josephine A D'Abbondanza; Ralph George; Sari Kives; Melinda A Musgrave
Journal:  Plast Surg (Oakv)       Date:  2020-06-04       Impact factor: 0.947

3.  The Impact of Combined Risk-Reducing Gynecological Surgeries on Outcomes in DIEP Flap and Tissue-Expander Breast Reconstruction.

Authors:  Avinash P Jayaraman; Travis Boyd; Savannah N Hampton; Nicholas T Haddock; Sumeet S Teotia
Journal:  Plast Surg (Oakv)       Date:  2020-05-22       Impact factor: 0.947

4.  Non-BRCA1/2 Breast Cancer Susceptibility Genes: A New Frontier with Clinical Consequences for Plastic Surgeons.

Authors:  Jordan D Frey; Ara A Salibian; Freya R Schnabel; Mihye Choi; Nolan S Karp
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-11-20

5.  Heterotopic autotransplantation of ovarian tissue in a large animal model: Effects of cooling and VEGF.

Authors:  Samara S Souza; Benner G Alves; Kele A Alves; Fabiana A S Brandão; Danielle C C Brito; Melba O Gastal; Ana P R Rodrigues; José R Figueireod; Dárcio I A Teixeira; Eduardo L Gastal
Journal:  PLoS One       Date:  2020-11-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.